TY - JOUR
T1 - Immunochemical property of human haptoglobin phenotypes
T2 - Determination of plasma haptoglobin using type-matched standards
AU - Cheng, Tsai Mu
AU - Pan, Ju Pin
AU - Lai, Shiau Ting
AU - Kao, Li Pin
AU - Lin, Hong Huei
AU - Mao, Simon J T
N1 - Funding Information:
We gratefully acknowledge the support of this work from the grants NHRI-EX94-9229SI (S. J. T. M) of National Health Research Institute, Taiwan, ROC, NSC 95-2313-B-009-003-MY2 (S. J. T. M) of National Science Council, Taiwan, ROC, and VGH90-2-60A (J. P. P) of Taipei Veterans General Hospital, Taiwan, ROC. We acknowledge James Lee for his critiques and comments which have made this paper more fluent.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/9
Y1 - 2007/9
N2 - Objectives: Haptoglobin (Hp) phenotypes 1-1, 2-1, and 2-2 are associated with inflammatory diseases. Since their biochemical structures are rather heterogeneous, it is necessary to accurately determine the plasma Hp levels. Design and methods: Immunodiffusion, immunoturbidimetric, and noncompetitive ELISA were conducted to determine the differences in immunoreactivity among Hp phenotypes and to verify that such difference may significantly affect the outcome of Hp determinations. A novel ELISA using phenotype-matched calibrators was performed to compared with a commercial GenWay ELISA kit using a single calibrator in normal healthy males. Results: In immunodiffusion and immunoturbidimetric assays, the immunoreactivity of Hp 1-1 was markedly higher than 2-1 and 2-2, while an opposite result was observed using an ELISA. The latter was primarily due to the repeated antigenic epitopes in polymeric 2-1 and 2-2. Thus, Hp levels could be significantly over- or underestimated depending on the method. An accurate ELISA could be achieved when using each type-specific Hp calibrator matched to each type subject. We show the mean levels of Hp 1-1 subjects (n = 16; 184 ± 42 mg/dL) to be significantly and differentially greater than 2-1 (n = 28; 153 ± 55 mg/dL) (p <0.05) and 2-2 (n = 24; 93 ± 54 mg/dL) (p <0.01) subjects. Conclusions: Due to the diverse immunochemical structure among the Hp types, phenotyping should be performed in all the patients and a type-matched Hp calibrator should be used in clinical Hp determination.
AB - Objectives: Haptoglobin (Hp) phenotypes 1-1, 2-1, and 2-2 are associated with inflammatory diseases. Since their biochemical structures are rather heterogeneous, it is necessary to accurately determine the plasma Hp levels. Design and methods: Immunodiffusion, immunoturbidimetric, and noncompetitive ELISA were conducted to determine the differences in immunoreactivity among Hp phenotypes and to verify that such difference may significantly affect the outcome of Hp determinations. A novel ELISA using phenotype-matched calibrators was performed to compared with a commercial GenWay ELISA kit using a single calibrator in normal healthy males. Results: In immunodiffusion and immunoturbidimetric assays, the immunoreactivity of Hp 1-1 was markedly higher than 2-1 and 2-2, while an opposite result was observed using an ELISA. The latter was primarily due to the repeated antigenic epitopes in polymeric 2-1 and 2-2. Thus, Hp levels could be significantly over- or underestimated depending on the method. An accurate ELISA could be achieved when using each type-specific Hp calibrator matched to each type subject. We show the mean levels of Hp 1-1 subjects (n = 16; 184 ± 42 mg/dL) to be significantly and differentially greater than 2-1 (n = 28; 153 ± 55 mg/dL) (p <0.05) and 2-2 (n = 24; 93 ± 54 mg/dL) (p <0.01) subjects. Conclusions: Due to the diverse immunochemical structure among the Hp types, phenotyping should be performed in all the patients and a type-matched Hp calibrator should be used in clinical Hp determination.
KW - ELISA
KW - Haptoglobin phenotypes
KW - HepG2
KW - Immunoreactivity
KW - Plasma concentration
KW - αβ and αβ chain expression
UR - http://www.scopus.com/inward/record.url?scp=34548131045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548131045&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2007.04.018
DO - 10.1016/j.clinbiochem.2007.04.018
M3 - Article
C2 - 17583688
AN - SCOPUS:34548131045
SN - 0009-9120
VL - 40
SP - 1045
EP - 1056
JO - Clinical Biochemistry
JF - Clinical Biochemistry
IS - 13-14
ER -